Abbott Laboratories $ABT Shares Sold by Park National Corp OH

Park National Corp OH lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 6.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 139,913 shares of the healthcare product maker’s stock after selling 10,269 shares during the quarter. Park National Corp OH’s holdings in Abbott Laboratories were worth $13,828,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Baker Tilly Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $323,000. Argent Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter valued at approximately $211,000. Miller Global Investments LLC lifted its stake in Abbott Laboratories by 17.3% during the third quarter. Miller Global Investments LLC now owns 1,890 shares of the healthcare product maker’s stock worth $187,000 after purchasing an additional 279 shares during the last quarter. Polaris Financial Partners acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $129,000. Finally, First Financial Bank Trust Division lifted its position in shares of Abbott Laboratories by 2.2% during the 3rd quarter. First Financial Bank Trust Division now owns 102,483 shares of the healthcare product maker’s stock worth $10,128,000 after buying an additional 2,180 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded up $2.63 during midday trading on Monday, reaching $100.13. The company’s stock had a trading volume of 3,498,474 shares, compared to its average volume of 11,315,676. The stock has a market capitalization of $173.27 billion, a P/E ratio of 32.45, a PEG ratio of 1.81 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a 50 day moving average price of $106.99 and a 200-day moving average price of $98.60. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $135.24.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Analyst Ratings Changes

A number of research analysts have issued reports on ABT shares. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research report on Thursday, August 13th. Citigroup boosted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Robert W. Baird began coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price for the company. Finally, Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $119.80.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.